secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGILENT TECHNOLOGIES, INC. (A)
CIK:        0001090872
Form:       8-K
Filed at:   2021-09-23T23:59:59+00:00
Accession:  0001564590-21-048719
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agilent appoints Pfizer CSO Mikael Dolsten to board effective Sept. 21
----------------------------------------------------------------------

- Dr. Mikael Dolsten, Pfizer CSO & President of Worldwide R&D and Medical, joins Agilent board.
- He co-led Pfizer's collaboration with BioNTech on COMIRNATY (COVID-19 vaccine).
- Dolsten brings 30+ years pharma experience and involvement in 30+ drug/vaccine approvals.
- He will serve on Audit & Finance and Nominating/Corporate Governance committees.
- Board size increased from 10 to 11; Dolsten stands for re-election at 2022 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/0001564590-21-048719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/a-8k_20210921.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-048719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer